Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q9BV47
UPID:
DUS26_HUMAN
Alternative names:
Dual specificity phosphatase SKRP3; Low-molecular-mass dual-specificity phosphatase 4; Mitogen-activated protein kinase phosphatase 8; Novel amplified gene in thyroid anaplastic cancer
Alternative UPACC:
Q9BV47; D3DSV8; Q9BTW0
Background:
Dual specificity protein phosphatase 26 (DUSP26), also known as Mitogen-activated protein kinase phosphatase 8, plays a crucial role in cellular processes by inactivating MAPK1 and MAPK3. This action leads to the dephosphorylation of heat shock factor protein 4, reducing its DNA-binding activity. DUSP26 is also involved in inhibiting MAP kinase p38 and preventing apoptosis in anaplastic thyroid cancer cells, alongside its ability to activate MAP kinase p38 and c-Jun N-terminal kinase (JNK).
Therapeutic significance:
Understanding the role of Dual specificity protein phosphatase 26 could open doors to potential therapeutic strategies.